10196. Zosuquidar

Nomenclature

CAS number: 167354-41-8
(αR)-4-[(1aα,6α,10bα)-1,1,-Difluoro-1,1a,6,10b-tetrahyrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-1-piperazineethanol; (2R)-anti-5-[3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy]quinoline.
C32H31F2N3O2; mol wt 527.60.
C 72.85%, H 5.92%, F 7.20%, N 7.96%, O 6.06%.

Description and references

Multidrug resistance (MDR) modulator; selective inhibitor of P-glycoprotein (P-gp), q.v. Prepn: J. R. Pfister, D. L. Slate, WO 9424107; eidem, US 5654304 (1994, 1997 both to Syntex); J. R. Pfister et al., Bioorg. Med. Chem. Lett. 5, 2473 (1995). Improved synthesis: C. J. Barnett et al., J. Org. Chem. 69, 7653 (2004). Effect on multidrug resistant cell lines: L. J. Green et al., Biochem. Pharmacol. 61, 1393 (2001). Specificity for P-gp: R. L. Shepard et al., Int. J. Cancer 103, 121 (2003). Clinical pharmacology and pharmacokinetics in patients with advanced malignancies: E. H. Rubin et al., Clin. Cancer Res. 8, 3710 (2002). Effect on pharmacokinetics of doxorubicin: S. Callies et al., Cancer Chemother. Pharmacol. 51, 107 (2003).

Chemical structure

Derivative

Trihydrochloride.

Nomenclature

CAS number: 167465-36-3
LY-335979; RS-33295-198.
C32H31F2N3O2.3HCl; mol wt 636.99.
C 60.34%, H 5.38%, F 5.97%, N 6.60%, O 5.02%, Cl 16.70%.

Properties

mp 190°.

Therapeutic Category

Antineoplastic adjunct (chemosensitizer).

Keywords

Antineoplastic Adjunct; Chemosensitizer